Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

T 89

Drug Profile

T 89

Alternative Names: Cardiotonic Pills; Compound Danshen Dripping Pills; Danshen Plus; Dantonic Capsule; Salvtonic; T89; Tasly Danshen Plus Capsule

Latest Information Update: 26 Jun 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tianjin Tasly Pharmaceutical
  • Developer Tasly Pharmaceutical Group; Tasly Pharmaceuticals, Inc.
  • Class Anti-infectives; Eye disorder therapies; Herbal medicines; Ischaemic heart disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Angina pectoris
  • Phase III Diabetic retinopathy
  • Phase II Respiration disorders

Most Recent Events

  • 15 Apr 2020 Tasly Pharmaceuticals withdrawn clinical trial in COVID-2019 infections in China (PO, Pills) (NCT04285190)
  • 26 Feb 2020 Tasly Pharmaceuticals plans a clinical trial for COVID-2019-infections (PO) (NCT04285190)
  • 10 Nov 2019 Tasly Pharmaceuticals completes a phase II trial for Respiration disorders (In volunteers) in USA (PO, Capsule) (NCT03552263)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top